Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial. The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
N/A for expanded access
Drug: Selpercatinib
Open-label expanded access
Other Name: LOXO-292
Other Name: LY3527723
Inclusion Criteria: - Diagnosis of cancer with RET activation, who are not eligible for an ongoing selpercatinib clinical trial and are medically suitable for treatment with selpercatinib - Have progressed or are intolerant to standard therapy, or no standard therapy option exists, or in the opinion of the investigator, are unlikely to derive significant clinical benefit from standard therapy - Have adequate organ function
Exclusion Criteria: - Currently enrolled in an ongoing clinical study of selpercatinib or another RET inhibitor - Clinically significant active cardiovascular disease or history of myocardial infarction within 6 months prior to study treatment; ongoing cardiomyopathy; or current prolongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF) interval greater than 470 milliseconds
Cancer Treatment Centers of America
Goodyear, Arizona, 85338
Mayo Clinic of Scottsdale
Scottsdale, Arizona, 85259
City of Hope National Medical Center
Duarte, California, 91010
University of California - San Diego
La Jolla, California, 92103
UCLA Medical Center
Los Angeles, California, 90095
Kaiser Permanente
Oakland, California, 94612
Irvine Medical Center
Orange, California, 92868
Kaiser Permanente Medical Center
Sacramento, California, 94814
Kaiser Permanente Medical Center
San Francisco, California, 94115
Univ of California San Francisco
San Francisco, California, 94115
Kaiser Permanente
Santa Clara, California, 95051
UCLA Medical Center
Santa Monica, California, 90404
Kaiser Permanente Medical Center
Vallejo, California, 94589
Memorial Cancer Institute
Hollywood, Florida, 33021
Mayo Clinic-Jacksonville
Jacksonville, Florida, 32224
Florida Hospital
Orlando, Florida, 32803
Tallahassee Memorial Hospital
Tallahassee, Florida, 32308
University Cancer and Blood Center
Athens, Georgia, 30607
Emory University
Atlanta, Georgia, 30329
University of Chicago Medicine-Comprehensive Cancer Center
Chicago, Illinois, 60637
Cancer Treatment Centers of America, Chicago
Zion, Illinois, 60099
Massachusetts General Hospital
Boston, Massachusetts, 02114
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
University of Michigan
Ann Arbor, Michigan, 48109
START Midwest
Grand Rapids, Michigan, 49546
Mayo Clinic
Rochester, Minnesota, 55905
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89169
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
Cleveland Clinic Foundation
Cleveland, Ohio, 44195
Ohio State University Medical Center
Columbus, Ohio, 43210
Cancer Treatment Centers of America
Tulsa, Oklahoma, 74133
University of Pennsylvania Hospital
Philadelphia, Pennsylvania, 19104
Eastern Regional Medical Center
Philadelphia, Pennsylvania, 19124
Oncology Consultants
Houston, Texas, 77030
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030
Virginia Cancer Specialists
Fairfax, Virginia, 22031
University of Wisconsin-Madison Hospital and Health Clinic
Madison, Wisconsin, 53792-4108
Contact Lilly at 1-800-LillyRx (1-800-545-5979)
Study Director
Eli Lilly and Company